Metabolic syndrome (MetS) forms a cluster of metabolic dysregulations including insulin
resistance, atherogenic dyslipidemia, central obesity, and hypertension. The pathogenesis …

The breakthrough discoveries of leptin and adiponectin more than two decades ago led to a
widespread recognition of adipose tissue as an endocrine organ. Many more adipose tissue …

Obesity epidemic reached the dimensions of a real global health crisis with more than one
billion people worldwide living with obesity. Multiple obesity-related mechanisms cause …

Chemerin is an adipocyte‐secreted protein with autocrine/paracrine roles on adipose
development and function as well as endocrine roles in metabolism and immunity. Following …

Non-alcoholic fatty liver disease (NAFLD) is recognized as the most common type of chronic
liver disease in Western countries. Insulin resistance is a key factor in the pathogenesis of …

The metabolic syndrome (MetS) confers an increased risk for both type 2 diabetes mellitus
(T2DM) and cardiovascular disease (CVD). Moreover, studies on adipose tissue biology in …

Objective—Obesity and hypertension are comorbid in epidemic proportion, yet their
biological connection is largely a mystery. The peptide chemerin is a candidate for …

Metabolic syndrome (MetS) is a cluster of cardiovascular risk factors that include obesity,
impaired glucose tolerance or diabetes, hyperinsulinemia, hypertension, and dyslipidemia …

Objective Chemerin is a novel adipokine. Previous research has investigated the
association between chemerin and clinical indices in patients with obesity or metabolic …

Background Different studies have evaluated changes in adipo/cytokine levels after bariatric
surgery and have given conflicting results. The adipo/cytokines, leptin and chemerin, and …